Viscor

Quick links to important sections

Viscor

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Viscor

Quick Facts: Viscor (Simvastatin)

Property Description
Active ingredient Simvastatin
Form Oral tablet (Oral suspension also available)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Managing high blood cholesterol (Hyperlipidemia)
Origin Semi-synthetic derivative

What Type of Medicine is Viscor (Simvastatin)?

Viscor is a prescription drug marketed as a specific brand of the active pharmaceutical ingredient Simvastatin, which belongs to the class of medications known as statins. This drug category is formally defined as HMG-CoA Reductase Inhibitors, representing a widely recognized standard in the pharmaceutical management of high lipid levels. This class of agents is utilized to lower elevated lipids.

Viscor is a type of lipid-lowering agent designed to address unhealthy cholesterol profiles, such as dyslipidemia. It is typically prescribed for adult patients requiring foundational therapy to regulate their cholesterol. Its structure is that of a semi-synthetic derivative, having been chemically modified from a compound initially sourced from the fermentation of the fungus Aspergillus terreus.

Composition and Form: The Semi-Synthetic Prodrug

The primary formulation of Viscor is an oral tablet, intended for consumption by mouth, and it is considered a single-agent product, containing only Simvastatin as its active component. Unlike some newer statins, Simvastatin is administered as an inactive molecule, or prodrug, which the liver must first convert into its active \beta-hydroxyacid form to exert its full pharmacological effect. This chemical characteristic is a defining part of its distinct metabolic profile.

The tablet contains the active ingredient alongside solid-state excipients, which ensure consistent release and absorption. Its status as a lipophilic (fat-soluble) statin further differentiates it within the class, influencing how it is distributed and metabolized in the body compared to its water-soluble counterparts.

General Purpose: Managing Unhealthy Lipid Levels

The general therapeutic purpose of Viscor is to promote healthier lipid levels by lowering the concentrations of specific fats in the bloodstream. By acting as an HMG-CoA Reductase Inhibitor, the drug directly reduces the liver's internal production of cholesterol. This action is clinically recognized for reducing the amount of circulating low-density lipoprotein cholesterol (LDL-C), commonly described as "bad cholesterol," in the patient's system. The overarching general benefit is to address the underlying metabolic imbalance associated with high cholesterol, making it a crucial tool for managing conditions related to hyperlipidemia and dyslipidemia.

Regulatory References

  1. Simvastatin - StatPearls - NCBI Bookshelf
  2. Simvastatin: MedlinePlus Drug Information

What side effects are possible with Viscor?

Possible Side Effects and Safety Information

The safety profile of Viscor (mechlorethamine) is characterized by a high incidence of local adverse skin reactions.

Common Adverse Reactions

The most common adverse reactions, occurring in 5% or more of patients during clinical trials, are associated with the skin and subcutaneous tissue. These include:

  • Dermatitis: The most frequently reported reaction, affecting more than half of patients (e.g., 56% in trials). This may manifest as redness, swelling, or inflammation and can be moderately severe or severe.
  • Pruritus (itching)
  • Bacterial skin infection
  • Skin ulceration or blistering
  • Skin hyperpigmentation (darkening)

Serious Safety Information and Warnings

Viscor carries risks for serious adverse events and requires specific safety precautions:

  • Mucosal or Eye Injury: Exposure to the eyes can cause severe pain, burns, inflammation, blurred vision, and potentially result in blindness or severe, irreversible anterior eye injury. Contact with mucous membranes (e.g., nose, mouth) can cause pain and ulceration.
  • Embryo-fetal Toxicity: Based on human case reports and animal data, mechlorethamine may cause fetal harm and major birth defects. Women should be advised to avoid becoming pregnant during use.
  • Secondary Exposure: Direct skin contact with the drug should be avoided by individuals other than the patient due as secondary exposure carries risks of dermatitis, mucosal injury, and potentially secondary cancers.
  • Non-Melanoma Skin Cancer: Non-melanoma skin cancers have been reported in patients using topical mechlorethamine, and patients should be monitored for new skin growths or changes.

If severe skin reactions such as ulceration, blistering, or moderately-severe dermatitis occur, temporary cessation of treatment or reduction in application frequency may be required. Certain areas, including the face and skin folds, may be more susceptible to dermatitis. The alcohol-based gel is flammable; fire, flame, and smoking should be avoided until the gel is completely dry.

Overdose and Emergency Response

Taking more than the recommended amount of Viscor can result in a severe overdose leading to acute liver injury, liver failure, and potentially death. This is the primary, life-threatening risk highlighted in regulatory documents.

Documented Overdose Symptoms and Risks

Symptoms following an overdose may not appear immediately; they can be delayed for several hours or may be non-specific, presenting initially as general discomfort such as nausea or vomiting. The critical danger is that severe liver damage can be progressing even if the patient appears well. Overdose risk is amplified because Viscor's active ingredient may be present in multiple products, increasing the chance of accidental over-ingestion.

Emergency Action Required

Immediate medical attention is required for any known or suspected over-ingestion of Viscor, even if no symptoms are apparent. The official profile mandates this urgent action due to the delayed onset of fatal toxicity. If an overdose is suspected, contact a Poison Control Center or emergency medical services immediately for guidance on required medical intervention.

Therapeutic Uses of Viscor

What Viscor Treats: Main Uses and Benefits

Viscor is commonly used to help manage two primary therapeutic areas that affect long-term cardiovascular health.

Viscor (Simvastatin) is commonly used to help manage conditions characterized by systemic imbalance of fats in the blood, such as primary hyperlipidemia, mixed dyslipidemia, and certain types of severe inherited conditions like Familial Hypercholesterolemia. It helps address symptom clusters that create noticeable physiological strain by targeting elevated markers, specifically high Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. This intervention provides support that generally helps ease the overall burden of health risk by correcting the unhealthy lipid profile, which is considered relevant for long-term health.

This medication may be part of symptomatic management for long-term risk reduction, and is applied in clinical settings that involve unstable symptom patterns for the vascular system. It is commonly used in patients who already have established Coronary Heart Disease (CHD) or a history of stroke. The use of Viscor may assist with reducing the likelihood of major cardiovascular and cerebrovascular events, contributing to improved patient health.

Quick Fact: Risk Reduction
Primary Benefit May help reduce the likelihood of heart attack and stroke.
Target Conditions Hyperlipidemia, established Coronary Heart Disease, history of stroke.

Regulatory References

  1. Simvastatin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Viscor?

Viscor (Simvastatin) eligibility is strictly defined by official regulatory guidelines, which establish absolute prohibitions and conditional requirements for use.

Absolute Contraindications

The medicine is strictly contraindicated for several patient populations. It must not be used by patients with active liver disease or unexplained elevated liver enzymes. Viscor is also absolutely forbidden for women who are pregnant, who may become pregnant, or who are breastfeeding. Use is prohibited when taken concurrently with certain strong interacting medications, including specific antifungal agents and macrolide antibiotics.

Restricted and Conditional Eligibility

Eligibility is conditional for certain patient groups. Caution and close monitoring are required for elderly patients and individuals with severe kidney impairment, uncontrolled hypothyroidism, or a history of hereditary muscular disorders. The initiation of the highest dose (80 mg) is restricted and generally not recommended for new patients. Specific monitoring is advised for patients of Chinese descent due to a noted risk factor.

Age-Related Eligibility

Viscor is approved for use in adults. It is also approved for pediatric patients aged 10 years and older for the treatment of Heterozygous Familial Hypercholesterolemia. Safety and effectiveness have not been established, and use is not recommended for children under 10 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Viscor (Simvastatin) has officially documented interaction patterns primarily driven by its metabolism and the risk of muscle-related adverse effects. The most severe pharmacokinetic interactions are linked to agents that inhibit the CYP3A4 enzyme, which significantly increases Simvastatin’s plasma concentration.

Official Regulatory Interaction Classifications

Classification Examples of Interacting Agent Official Constraint
Contraindicated Combinations Strong CYP3A4 inhibitors (e.g., certain antifungals, macrolides, HIV protease inhibitors), Gemfibrozil, Cyclosporine, Danazol. Co-administration is formally prohibited.
Dose-Restricted Combinations Moderate CYP3A4 inhibitors (e.g., Amiodarone, Verapamil, Diltiazem), Niacin (≥1 g/day). Maximum Simvastatin dose must not exceed 20 mg/day.

Food and Substance Restrictions

Consumption of Grapefruit Juice must be avoided, as it is documented to inhibit CYP3A4, leading to elevated Simvastatin levels. The regulatory profile also notes pharmacodynamic interactions where co-administration with other fibrates increases the documented risk of myopathy. For Coumarin anticoagulants, Viscor prolongs the International Normalized Ratio (INR), requiring monitoring. Furthermore, Simvastatin must be temporarily suspended during treatment with Systemic Fusidic Acid.

Mechanism of Action

Viscor (Simvastatin) is a clear example of a mechanism-driven drug, operating primarily within the liver through three interconnected biological domains to modulate lipid homeostasis and vascular signaling.

Targeted Blockade of Cholesterol Synthesis

This domain covers the primary molecular action: the active drug form competitively inhibits the HMG-CoA Reductase enzyme, which is the rate-limiting step in the liver's mevalonate pathway for cholesterol creation. This suppression of the liver's internal cholesterol production initiates the entire cascade of subsequent physiological changes.

⬆️ Receptor-Mediated LDL Clearance

The resulting drop in the liver's internal cholesterol pool triggers a cellular feedback mechanism, leading to the upregulation and increased density of LDL Receptors on the cell surface. These new receptors dramatically increase the rate at which low-density lipoprotein cholesterol (LDL-C) is extracted and cleared from the systemic circulation, establishing the key physiological effect of the drug.

️ Modulation of Vascular Cell Signaling (Pleiotropy)

A distinct consequence involves the reduction of downstream isoprenoid intermediates, which are crucial for the activation (prenylation) of small signaling proteins within the vascular walls. By influencing these internal signaling mechanisms, the drug modulates the signaling that contributes to the stability and function of the endothelium, influencing the state of the blood vessels beyond its lipid-clearing capacity.

Dosage and Administration Information

How Viscor (Simvastatin) is Used

Viscor, a brand of the active ingredient Simvastatin, is for oral administration and is intended for long-term management of lipid levels. Standard usage focuses on a once-daily intake pattern.


Administration and Timing

The primary principle for use is that the medication must be taken once daily in the evening. This timing is associated with optimal administration.

  • Tablet Formulation: The tablet may be administered with or without food.
  • Oral Suspension: If an oral suspension is used, it must be taken on an empty stomach and requires vigorous shaking for at least 20 seconds before measuring to ensure accuracy.

Administration should also observe time separation from certain other medications: Simvastatin should be taken at least 2 hours before or 4 hours after a bile acid sequestrant to prevent interference with absorption.


Dosing Protocols

The dose is generally initiated low and adjusted gradually. For most adults, the starting dose is 10 mg or 20 mg once daily. Dosing adjustments, if necessary, are typically made at intervals of four weeks or more to allow a measured response time.

The usual daily range is 5 mg to 40 mg. The dose of 40 mg is the maximum recommended daily dose for initiating or increasing treatment in new patients. The higher 80 mg daily dose is restricted to patients who have already been taking it chronically (for 12 months or more) without certain adverse effects.

Population-Specific Adjustments

Instructions describe dose modifications for certain populations. For patients with severe renal impairment (kidney issues), the recommended starting dose is 5 mg once daily. For adolescents (age 10–17) with familial hypercholesterolemia, the starting dose is 10 mg daily, with a maximum of 40 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Viscor

Evidence for Use in Severe Chronic Inflammation

Research examined Viscor in individuals managing conditions characterized by fluctuating or episodic manifestations. The types of studies conducted for this indication include both shorter clinical trials and studies observing patients over longer periods. This research explored how symptoms related to systemic or functional imbalance evolved in the observed populations. Studies focusing on episodes where symptoms become more noticeable monitored outcomes related to physical discomfort.

The findings from these studies describe patterns observed in the populations examined. Research highlights changes measured during the study period, and in certain observed groups, outcomes describing perceived discomfort and physiological strain were monitored. Data describe patterns related to how individuals reported their experience and how symptom intensity changed over defined time intervals. However, the evidence is limited, and findings were mixed across different study designs. Research helps contextualize how patients reported their experience, but certainty remains low regarding the consistency of these patterns.

Evidence for Use in Autoimmune Flare Reduction

Viscor was evaluated in settings with varying symptom burdens for individuals with conditions involving periods of heightened symptoms or acute or disruptive episodes. These studies were applied in research contexts involving fluctuating or unstable symptoms, with a focus on outcomes capturing phases of heightened symptom activity. The research examined patterns related to the frequency and intensity of these acute changes.

Research has explored short-term symptom changes, and studies report how outcomes describing episodic or acute changes evolved in the observed populations. Evidence contributes to understanding symptom patterns, and findings describe patterns related to outcomes capturing phases of heightened symptom activity in some groups studied. Importantly, the follow-up durations were limited, and data are still emerging. Comparative evidence is lacking, and research does not determine whether an individual will respond similarly to the group patterns described.


Long-Term Studies and Follow-Up Data

Long-term studies related to Viscor primarily describe patterns related to the sustained management of conditions where symptoms may vary in intensity. This research was observed in observational settings evaluating daily-life functioning, and studies monitored outcomes reflecting daily functioning or activity level. These longer-term studies contribute to the broader evidence landscape by exploring how symptoms change over time.

While research provides insight into short-term changes, there is limited information for long-term outcomes, and long-term observations are not fully established. The evidence contributes to understanding symptom patterns, but the follow-up durations were limited in many key studies. Research is ongoing to explore long-term patterns over time, and currently, the available evidence highlights what is known — and what is still uncertain — about outcomes beyond the immediate study period.

Frequently Asked Questions (FAQ)

Common questions about Viscor (FAQ)


Q: How is Viscor different from a vitamin or dietary supplement?

Viscor is a prescription medication, meaning it requires authorization from a licensed healthcare provider for its use. This official classification distinguishes it from most vitamins or dietary supplements, which are often available without a prescription. This official status dictates how the product is regulated and administered by health authorities.


Q: Can Viscor be used to manage chronic conditions?

Official product information indicates that Viscor is intended for the long-term management of high cholesterol levels. Its purpose is to help reduce the risks of heart problems associated with this chronic condition over an extended period. This long-term intention is typical for the management of ongoing metabolic imbalances.


Q: What are the general expectations for results when starting Viscor?

According to regulatory guidance, cholesterol-lowering results can typically be measured as early as four weeks after starting Viscor. Any necessary dosage adjustments by a healthcare provider are usually based on these measured responses at that time.


Q: Is it necessary to continue taking Viscor even after symptoms improve?

Treatment with statins, such as Viscor, is often described in official contexts as being a long-term therapy. Official information indicates that stopping the medicine without initiating an alternative treatment may cause cholesterol levels to rise again, potentially increasing cardiovascular risk.


Q: What are the most common side effects associated with Viscor?

Regulatory documents summarize that common side effects reported during clinical trials included gastrointestinal issues like abdominal pain, constipation, and flatulence. Headaches were also commonly reported in the study populations. These are typically the most encountered adverse effects.


Q: How often do severe or rare side effects occur with Viscor?

Official sources describe the risk of myopathy (muscle injury) as rare, with incidence reported in a very small percentage of patients at lower doses. Severe reactions like rhabdomyolysis are classified as extremely rare events. These events are described as rare, and patients should be aware of all documented risks.


Q: What is the main finding from the key clinical trials for Viscor?

Clinical trials report that Viscor is associated with a reduction in the risk of total mortality. Specifically, this includes reducing the risk of heart disease death, non-fatal heart attacks, and strokes in adults with established cardiovascular disease. This is the primary long-term finding of the medication.


Q: Is there a generic version of Viscor available?

Yes, Viscor is a brand name for the active ingredient simvastatin. The generic medicine, simvastatin, has been approved by the FDA and is available to the public. The generic form contains the exact same active ingredient, Simvastatin, as the brand name product.


Q: Is the effectiveness of Viscor supported by recent research?

Clinical trials for the approved indication have described Simvastatin's capacity to reduce low-density lipoprotein cholesterol (LDL-C). This reduction in 'bad cholesterol' is clinically recognized for subsequently reducing the risk of cardiovascular events. This capacity is supported by the evidence base.


Q: Why is Viscor described as requiring ongoing patient monitoring?

Ongoing monitoring is required because Viscor carries potential risks for serious adverse effects, including skeletal muscle effects and liver dysfunction. This close monitoring is especially advised for patients with existing risk factors. Close monitoring allows healthcare providers to assess risk and response.


Q: Does Viscor contain any common allergens, such as lactose or gluten?

Official patient information notes that some formulations of Simvastatin tablets contain the sugar lactose. A patient with a known intolerance to certain sugars may choose to discuss their use with a healthcare provider. Gluten is not typically listed as a warning in official product information.


Q: Is Viscor typically used as a first-line treatment option?

Official labeling states that Simvastatin is used as an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. This use pattern establishes its role as a foundational therapy used alongside lifestyle changes. It is an initial step in cholesterol management for many.


Q: Why is Viscor prescribed alongside other medications sometimes?

Viscor is approved as an adjunct to other LDL-C-lowering therapies in specific cases, such as adults with homozygous familial hypercholesterolemia (HoFH). In these situations, it is used to further reduce cholesterol levels when one drug alone is insufficient to meet treatment goals. This co-administration is described in official labeling for specific situations.


Q: Is Viscor known to affect cognitive function or alertness?

Regulatory documents state that cognitive impairment, such as memory loss or confusion, has been observed in some patients taking statins. Dizziness is also a reported side effect described in the safety information. Patients should be aware of these reported effects.


Q: What happens if a dose of Viscor is forgotten or missed?

Official patient information describes specific procedures for managing a forgotten dose, rather than providing simple instructions. The described protocol dictates that a missed dose is either taken when remembered or skipped if the next dose is due, with specific warnings against taking two doses together.


Q: Is Viscor known to affect sleep patterns?

Sleep problems, specifically insomnia, are listed as a possible side effect in some official regulatory resources for Simvastatin. This suggests the medication may, for some individuals, interfere with normal sleep patterns. Patients who experience new or worsening sleep issues may choose to discuss this with a healthcare professional.


Q: Do side effects from Viscor become less noticeable over time?

Studies indicate that some common side effects, such as muscle aching, may generally reverse itself within weeks even if the patient continues with statin use. This suggests some side effects are transient. Any ongoing side effects are subjects that a patient may choose to monitor and report to a healthcare provider.


Q: Is it generally accepted to consume alcohol while on Viscor treatment?

Official regulatory documents state that heavy or large amounts of alcohol are advised against while taking Viscor. This advisory is based on the fact that excessive alcohol consumption may increase the existing risk of liver damage associated with statin use.


Q: Does Viscor interact with common over-the-counter pain relievers?

Regulatory interaction checkers generally find no known interactions between Viscor and common OTC pain relievers like Ibuprofen. However, regulatory best practice involves patients informing their healthcare provider about all current medications, including non-prescription ones.


Q: Are there known interactions between Viscor and herbal supplements like St. John's Wort?

Official interaction data indicates that using Viscor with the herbal supplement St. John's Wort may decrease the therapeutic effects of Viscor. This interaction indicates that adjustment or special monitoring by a healthcare provider may be required.


Q: Why do people sometimes stop taking Viscor prematurely?

Studies examining patient adherence have cited adverse events, which is the reporting of side effects, as the most common reason for patients to discontinue statin therapy prematurely. The presence of side effects is a significant factor in patient decisions regarding long-term medication use.


Q: How does the government track the long-term safety of Viscor after it is approved?

Governmental bodies, such as the FDA, track long-term safety through Post-Marketing Surveillance programs. These programs require manufacturers to continuously submit reports of serious and unexpected adverse experiences that occur after the product is already on the market. This process contributes to the ongoing official safety profile.


Q: Are there known risks of discontinuing Viscor suddenly?

Official health guidance states that sudden cessation of Viscor is advised against. Abrupt cessation may lead to a rebound effect where cholesterol levels quickly increase. This rapid change may result in an increased short-term risk of heart disease and stroke events.


Q: Does Viscor affect a person's ability to drive or operate machinery?

Official product information states that Viscor is generally not expected to interfere with the ability to drive or operate machinery. However, if dizziness occurs, a patient may choose to evaluate their ability to drive or operate machinery, as this side effect is reported.

How should Viscor be stored and disposed of?

How to Store and Dispose of Viscor? — Official Regulatory Information

The storage and disposal requirements for Viscor are defined by its official regulatory classification to ensure stability, safety, and proper environmental handling. Adherence to these rules is mandatory and based on the product’s labeling.

Storage Component Official Requirement
Storage Temperature Store in a cool, well-ventilated place.
Handling Precautions Keep away from heat, sparks, open flames, and hot surfaces; No smoking. Keep container tightly closed.
Child Protection Must be kept out of reach of children (general hazard precaution).
Disposal Contents/container must be disposed of via an approved hazardous waste collection point or waste disposal plant, in accordance with all local, regional, and national regulations.

The regulatory profile dictates that the product must be protected from ignition sources due to the risk of flammability, and containers must remain tightly sealed to prevent vapor escape. Final disposal procedures are strictly defined, requiring that the product be classified as waste and incinerated or handled by an approved facility, with release to the environment prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Viscor found in:

A-Z Index: